Clinical Trials Development Workshop
The Clinical Trials Development Workshop is free and appropriate for clinical investigators of all experience levels looking to increase clinical trial working knowledge. It is led by experienced physicians and basic scientists across health sciences.
Hosted by the College of Medicine – Tucson, this workshop is sponsored by a grant from the Arizona Biomedical Research Commission (ABRC). ABRC-funded events strive to deliver high-quality educational resources to support Arizona researchers to become leaders in biomedical research fields, successfully compete for external support and translate research findings to address critical medical needs and improve health outcomes.
Dr. Shroff is associate professor of medicine and associate dean of clinical and translational research at the UArizona College of Medicine – Tucson, chief of the Section of Gastrointestinal (GI) Medical Oncology, and leader of the UArizona Cancer Center GI Clinical Research Team. Her research focuses on clinical and translational research in pancreatic and hepatobiliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the hepatobiliary subcommittee co-chair for the Southwest Oncology Group (SWOG) and as a nominating committee member for the American Society of Clinical Oncology (ASCO). Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national PI for SWOG 1815 which is investigating a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase two study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area.
Dr. Scott is an academic medical oncologist specializing in translational research and treatment of gastrointestinal malignancies. He is originally from Tucson, Arizona, and earned a Baschelor of Science in molecular and cellular biology at UArizona. He attended medical school and earned his medical degree from UArizona College of Medicine – Tucson. He then completed his internal medicine residency and hematology/oncology fellowship training at the University of Colorado Hospital. During his time at UCH, he received specialized training in translational and clinical research in gastrointestinal malignancies. He joined the Banner-University of Arizona Cancer Center as faculty with the GI oncology group in fall 2016.
Melton-Lopez currently serves as the director of the Human Subjects Protection Program with UArizona Research, Innovation & Impact (RII). She has over 12 years of experience in ethical conduct of research. She has programmatic oversight responsibility for the Human Subjects Protection Program and the Institutional Review Boards. Melton-Lopez maintains active certifications as a certified IRB professional (CIP) and has extensive knowledge of human subject regulations, Department of Defense and Food and Drug Administration regulations.
Ellis Langford has an extensive background in legal compliance, including collaborations with the Food and Drug Administration as well as Health and Human Services. She has extensive knowledge of conflict of interest and commitment policies, and how they do and do not intersect with federal and local regulations. She collaborates with all research administration and compliance offices, outside institutions and the Association of American Medical Colleges.
Zajac works to develop highly impactful and sustainable administration research services, tools and strategies consistent with UArizona Health Sciences-sponsored research goals. Prior to joining the UArizona Health Sciences, Zajac held several positions with the University of Chicago, including executive director, pre-and post-award management, in the Department of Medicine; director of sponsored programs; senior manager of contracts; and grants and contracts manager in University Research Administration. She also was research administrator with the Office of Research and Sponsored Programs at Northwestern University. She is a member of the National Council of University Research Administration and has served as a study section member for the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI).
Dr. Parthasarathy's current research is supported by the NIH/NHLBI, Patient-Centered Outcomes Research Institute (PCORI) and industry funding. Dr. Parthasarathy is the current chairperson for the Sleep Research Network and was previously the chairman of the Sleep Disorders Research Advisory Board to the NIH; and currently serves as associate editor for the Journal of Clinical Sleep Medicine and serves on the editorial board of the American Journal of Respiratory and Critical Care Medicine. His research focuses on sleep and breathing in both ambulatory and critically ill patients. Specifically, his current PCORI-funded initiative is addressing peer-driven intervention for promotion of CPAP adherence. His NIH-funded research investigates the relationship between sleep and inflammation in the critically ill and in the general population. He is committed to training and fostering young scientific investigators in the pursuit of sleep and circadian science.
Dr. Vanderah is head and professor of pharmacology, and is a professor in the departments of neurology and anesthesiology. His research interests include mechanisms of cancer pain, neuronal integration in pain pathways, neurochemical release during conditions of neuropathy, neuronal plasticity, opioid receptor pharmacology and novel targets for drug discovery. He is author of over 135 original research articles.
Dr. LaFleur's scientific expertise is in immunobiology, oncology and aging. Most of her methodologic work is in statistical methods for precision healthcare, specifically biomarkers. Dr. LaFleur was a tenure-track faculty in Biostatistics for 15 years, before joining the UArizona Mel and Enid Zuckerman College of Public Health in 2008 as an associate professor. During her time in industry, she developed several molecular biomarkers that led to patents and some were submitted and approved for use by the FDA. She also managed customer relations for Key Opinion Leaders and the pharmaceutical industry. She joined the UArizona community again in 2018 as a research professor in the BIO5 Institute and is currently the core director and project lead on several program project grants at UArizona.